Report

Global Systemic Scleroderma Treatment Market Size study, by Drug Class (Immunosuppressors, Phosphodiesterase 5 inhibitors - PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers and Others), and Regional Forecasts 2021-2027

  • Publish Date: Mar,2022
  • Report ID: QI037
  • Page : 250
  • Report Type : PDF (Email)
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
1.2.1. Systemic Scleroderma Treatment Market, by Region, 2019-2027 (USD Billion)
1.2.2. Systemic Scleroderma Treatment Market, by Drug Class, 2019-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Systemic Scleroderma Treatment Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Systemic Scleroderma Treatment Market Dynamics
3.1. Systemic Scleroderma Treatment Market Impact Analysis (2019-2027)
3.1.1. Market Drivers
3.1.1.1. Rising prevalence of systemic scleroderma
3.1.1.2. Grant of supplemental approvals to pharmaceutical companies
3.1.2. Market Restraint
3.1.2.1. Lack of validated results
3.1.2.2. Failure of clinical trials
3.1.3. Market Opportunities
3.1.3.1. Rising focus of biotechnology industry towards development of new therapies
Chapter 4. Global Systemic Scleroderma Treatment Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Systemic Scleroderma Treatment Market, by Drug Class
5.1. Market Snapshot
5.2. Global Systemic Scleroderma Treatment Market by Drug Class, Performance - Potential Analysis
5.3. Global Systemic Scleroderma Treatment Market Estimates & Forecasts by Drug Class 2018-2027 (USD Billion)
5.4. Systemic Scleroderma Treatment Market, Sub Segment Analysis
5.4.1. Immunosuppressors
5.4.2. Phosphodiesterase 5 inhibitors - PHA
5.4.3. Endothelin Receptor Antagonists
5.4.4. Prostacyclin Analogues
5.4.5. Calcium Channel Blockers
5.4.6. Others
Chapter 6. Global Systemic Scleroderma Treatment Market, Regional Analysis
6.1. Systemic Scleroderma Treatment Market, Regional Market Snapshot
6.2. North America Systemic Scleroderma Treatment Market
6.2.1. U.S. Systemic Scleroderma Treatment Market
6.2.1.1. Drug Class breakdown estimates & forecasts, 2018-2027
6.2.2. Canada Systemic Scleroderma Treatment Market
6.3. Europe Systemic Scleroderma Treatment Market Snapshot
6.3.1. U.K. Systemic Scleroderma Treatment Market
6.3.2. Germany Systemic Scleroderma Treatment Market
6.3.3. France Systemic Scleroderma Treatment Market
6.3.4. Spain Systemic Scleroderma Treatment Market
6.3.5. Italy Systemic Scleroderma Treatment Market
6.3.6. Rest of Europe Systemic Scleroderma Treatment Market
6.4. Asia-Pacific Systemic Scleroderma Treatment Market Snapshot
6.4.1. China Systemic Scleroderma Treatment Market
6.4.2. India Systemic Scleroderma Treatment Market
6.4.3. Japan Systemic Scleroderma Treatment Market
6.4.4. Australia Systemic Scleroderma Treatment Market
6.4.5. South Korea Systemic Scleroderma Treatment Market
6.4.6. Rest of Asia Pacific Systemic Scleroderma Treatment Market
6.5. Latin America Systemic Scleroderma Treatment Market Snapshot
6.5.1. Brazil Systemic Scleroderma Treatment Market
6.5.2. Mexico Systemic Scleroderma Treatment Market
6.6. Rest of The World Systemic Scleroderma Treatment Market
Chapter 7. Competitive Intelligence
7.1. Top Market Strategies
7.2. Company Profiles
7.2.1. Boehringer Ingelheim International GmbH
7.2.1.1. Key Information
7.2.1.2. Overview
7.2.1.3. Financial (Subject to Data Availability)
7.2.1.4. Product Summary
7.2.1.5. Recent Developments
7.2.2. Gilead Sciences Inc.
7.2.3. GlaxoSmithKline plc
7.2.4. Novartis AG
7.2.5. Pfizer Inc.
7.2.6. Hoffmann La Roche Ltd.
7.2.7. Johnson & Johnson Services, Inc.
7.2.8. United Therapeutics
7.2.9. Eli Lilly and Company
7.2.10. Mylan N.V.

Chapter 8. Research Process
8.1. Research Process
8.1.1. Data Mining
8.1.2. Analysis
8.1.3. Market Estimation
8.1.4. Validation
8.1.5. Publishing
8.2. Research Attributes
8.3. Research Assumption